Highlights

  • 1

    Panel discussion of the highlights in precision medicine in breast cancer from ASCO 2019. A data review of the oral presentations, posters and abstracts presented on patients with hormonal receptor positive in EBC and MBC, TNBC, HER2.

Summary

Panel discussion of the highlights in precision medicine in breast cancer from ASCO 2019. A data review of the oral presentations, posters and abstracts presented on patients with hormonal receptor positive in EBC and MBC, TNBC, HER2.

A discussion of when to use prognostic tests such as the Oncotype DX, BCI (H/I) prognostic assay and other available assays which may benefit hormone positive patients and how these tests may impact clinical practice.

Interviewer

User

Edith Perez

Jacksonville, Forida

Edith A. Perez, M.D., is the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine. Dr. Perez is a cancer speciali...

Participant

User

John Bartlett

Edinburgh, Scotland

Personalized medicine requires personalized diagnostics. As the impact of the deep molecular characterization of cancer and other diseases is translat...

Participant

User

Vered Stearns, M.D.

Professor of Oncology Co-Director, Breast and ...
at Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine

Baltimore, MD, USA

Dr. Stearns co-leads the Breast and Ovarian Cancer Program at the Johns Hopkins Kimmel Cancer Center. She is the associate director for oncology...

Participant

User

Joseph Gligorov MD., PhD.

Professor of Medical Oncology Executive Direc ...
at Institut Universitaire de Cancérologie APHP.6, Sorbonne University

Paris, France

Professor Gligorov works in the oncology unit at Tenon Hospital, in Paris. He is also a member of the Scientific Board of APREC, ...

Comments (0)